Development of new treatments for extranodal NK/ XXXX in Japan.

@entity1 @entity137 @entity706 @entity784 @entity47390 @entity4445 @entity35 @entity408
@entity47390 / @entity784 , nasal type (ENKL), accounts for less than 3% of @entity706 in Japan. Based on the results of prospective clinical trials, ENKL treatment has dramatically improved during the last decade in Japan. The @entity706 Study Group of the Japan Clinical Oncology Group (JCOG) conducted a phase I/II study (JCOG0211) of concurrent chemoradiotherapy for newly-diagnosed, localized ENKL. The trial showed an excellent 5-year overall survival rate (70%) and acceptable @entity137 of @entity35 /3DeVIC. The NK-cell Tumor Study Group in Japan, together with Asian collaborators, conducted clinical trials ( @entity408 -PI _ PII) of @entity408 chemotherapy for @entity1 with newly-diagnosed stage IV, or relapsed/refractory ENKL. The overall response rate for 2 cycles of @entity408 in 38 evaluated @entity1 was 79%. The 2013 Japanese Society of Hematology guidelines recommend RT-2/3DeVIC for the treatment of newly-diagnosed ENKL of stage IE and contiguous stage IIE with cervical node involvement. For other ENKL, @entity408 or other @entity4445 -containing chemotherapies are recommended. A large retrospective study evaluating the efficacy and @entity137 of these new treatments in clinical practice is currently underway in Japan. Close cooperation between radiation oncologists and international collaboration will be the key factors in developing better first-line treatments for ENKL.
